Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 161

1.

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.

Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI, Beer TM.

JAMA Oncol. 2019 Dec 12. doi: 10.1001/jamaoncol.2019.4636. [Epub ahead of print]

PMID:
31830211
2.

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.

Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H.

J Clin Oncol. 2019 Dec 12:JCO1902768. doi: 10.1200/JCO.19.02768. [Epub ahead of print]

PMID:
31829902
3.

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.

Li Y, He Y, Butler W, Xu L, Chang Y, Lei K, Zhang H, Zhou Y, Gao AC, Zhang Q, Taylor DG, Cheng D, Farber-Katz S, Karam R, Landrith T, Li B, Wu S, Hsuan V, Yang Q, Hu H, Chen X, Flowers M, McCall SJ, Lee JK, Smith BA, Park JW, Goldstein AS, Witte ON, Wang Q, Rettig MB, Armstrong AJ, Cheng Q, Huang J.

Sci Transl Med. 2019 Dec 4;11(521). pii: eaax0428. doi: 10.1126/scitranslmed.aax0428.

PMID:
31801883
4.

Has Mismatch Repair-Deficient Cancer Met Its MATCH?

Brown LC, Armstrong AJ.

J Clin Oncol. 2019 Dec 3:JCO1902860. doi: 10.1200/JCO.19.02860. [Epub ahead of print] No abstract available.

PMID:
31794325
5.

Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.

Gupta S, Hovelson DH, Kemeny G, Halabi S, Foo WC, Anand M, Somarelli JA, Tomlins SA, Antonarakis ES, Luo J, Dittamore RV, George DJ, Rothwell C, Nanus DM, Armstrong AJ, Gregory SG.

Genes Chromosomes Cancer. 2019 Nov 9. doi: 10.1002/gcc.22824. [Epub ahead of print]

PMID:
31705765
6.

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

George DJ, Halabi S, Healy P, Jonasch D, Anand M, Rasmussen J, Wood SY, Spritzer C, Madden JF, Armstrong AJ.

Urol Oncol. 2019 Sep 12. pii: S1078-1439(19)30333-3. doi: 10.1016/j.urolonc.2019.08.015. [Epub ahead of print]

PMID:
31522863
7.

Molecular determinants for enzalutamide-induced transcription in prostate cancer.

Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, Huang J, Chen Z, Wang Q.

Nucleic Acids Res. 2019 Nov 4;47(19):10104-10114. doi: 10.1093/nar/gkz790.

8.

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ.

Prostate. 2019 Nov;79(15):1752-1761. doi: 10.1002/pros.23899. Epub 2019 Sep 9.

PMID:
31497882
9.

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR.

Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4.

PMID:
31483485
10.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A.

J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22.

PMID:
31329516
11.

Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.

Urol Oncol. 2019 Nov;37(11):813.e1-813.e9. doi: 10.1016/j.urolonc.2019.06.015. Epub 2019 Jul 19.

PMID:
31327751
12.

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.

Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung, Parli T, Krivoshik A, Beer TM.

Eur Urol Oncol. 2019 Nov;2(6):677-684. doi: 10.1016/j.euo.2018.11.005. Epub 2018 Dec 3.

13.

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ.

Cancer Med. 2019 Aug;8(10):4644-4655. doi: 10.1002/cam4.2375. Epub 2019 Jul 3.

14.

Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Scher HI, Antonarakis ES, George DJ.

J Clin Oncol. 2019 Aug 20;37(24):2184-2186. doi: 10.1200/JCO.19.01230. Epub 2019 Jul 2. No abstract available.

PMID:
31265357
15.

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, Spritzer C, Davies C, Rothwell C, Ware K, Somarelli JA, Wood K, Ribar T, Giannakakou P, Zhang J, Gerber D, Anand M, Foo WC, Halabi S, Gregory SG, George DJ.

PLoS One. 2019 May 28;14(5):e0216934. doi: 10.1371/journal.pone.0216934. eCollection 2019.

16.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
17.

Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.

McNamara MA, Oyekunle T, Chin BB, Oldan J, Anand A, Ritz M, Shantzer L, Anand M, Armstrong AJ, George DJ.

Prostate. 2019 Jul;79(10):1106-1116. doi: 10.1002/pros.23822. Epub 2019 May 2.

PMID:
31045266
18.

Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.

Mota JM, Armstrong AJ, Larson SM, Fox JJ, Morris MJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):522-530. doi: 10.1038/s41391-019-0151-4. Epub 2019 Apr 29. Review.

PMID:
31036925
19.

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):588-592. doi: 10.1038/s41391-019-0144-3. Epub 2019 Apr 12.

20.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ.

J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13.

PMID:
30865549

Supplemental Content

Loading ...
Support Center